Home > Products > CA19-9 & CD3 > Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG)

Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG)  (CAT#: BSIG-026)

Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CA19-9 and anti-CD3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Ovarian cancer; Pancreatic cancer; Gastric cancer therapy.
Datasheet INQUIRY

Specifications

Targets
CA19-9 & CD3
Type
IgG-IgG
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Ovarian cancer; Pancreatic cancer; Gastric cancer

Targets

Target 1
CA19-9
Alternative Names
CA19-9; Cancer antigen 19-9; sialylated Lewis (a) antigen; Carbohydrate antigen 19-9
Target 2
CD3
Gene ID
UniProt ID
Alternative Names
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CA19-9 & CD3"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG) (BSIG-026). Click the button below to contact us or submit your feedback about this product.